middle.news
Atomo Diagnostics Accelerates US Growth Following FebriDx FDA CLIA Waiver
10:24am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Atomo Diagnostics Accelerates US Growth Following FebriDx FDA CLIA Waiver
10:24am on Tuesday 28th of April, 2026 AEST
Key Points
FDA CLIA waiver boosts US Pascal cassette demand
Over $2 million in sales orders secured in Q3
$3 million capital raise completed, debt-free balance sheet
New international customers and expanded product pipeline
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Atomo Diagnostics (ASX:AT1)
OPEN ARTICLE